Giuliana Grossi

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.

ED dizziness visits see rising MRI use at discharge; exam-guided imaging helps detect missed strokes and informs secondary prevention.

Across 39 patients in 2 cohorts, rapid microbe reduction, high wound closure, restored warmth and sensation, and avoided amputations were observed.

Linda Stein Gold, MD, shares insights on new therapeutic options for patients with various psoriasis subtypes and psoriatic arthritis.

Oral Wegovy shifts GLP-1 obesity costs: insurance may match injectables, while cash-pay and pharmacy platforms unlock lower prices and aid programs.

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin.

Experts propose a 6-parameter framework for ATTR-CM monitoring and disease progression in transthyretin amyloid cardiomyopathy.

Collaborative care use has surged 26-fold, but state reimbursement gaps leave many patients without integrated mental health care in primary care.

Rising stroke rates in young adults highlight the need to manage blood pressure and cholesterol early and improve outcomes through better ICU care.

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Maui Derm 2026 showcased groundbreaking advancements in dermatology, focusing on biologics, innovative treatments, and future technologies for skin health.

Aquestive Therapeutics receives a complete response letter for dibutepinephrine (Anaphylm), a sublingual epinephrine therapy.

Prior authorization remains a major health care barrier, causing delays and frustrations for insured adults seeking necessary treatments.

Margaret Krackeler, MD, discusses real-world data supporting the switch from ibrutinib to zanubrutinib for chronic lymphocytic leukemia.

Explore critical health equity issues as barriers to care access and health disparities that impact treatment for allergic rhinitis and childhood vaccinations.

Discover how innovations in biology and engineering are transforming dermatology, featuring breakthroughs in laser therapies and precision medicine.

Vivian Shi, MD, discusses the evolving strategies for managing hidradenitis suppurativa, including biologics and combination therapies, at Maui Derm 2026.

A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.

Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.

Experts discuss groundbreaking therapies in dermatology at Maui Derm 2026, addressing complex skin diseases and enhancing patient care with innovative treatments.

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Daniel Siegel, MD, discusses a loophole he looks out for in ICD-10 coding and billing.

Maui Derm 2026 showcases groundbreaking clinical trial data and innovative strategies in dermatology.

Patients with allergic rhinitis face prolonged symptoms and inadequate treatment, highlighting a need for better awareness and access to allergen immunotherapy.

Research reveals that socioeconomic status significantly impacts survival rates in young adults with metastatic colorectal cancer, emphasizing the need for health equity initiatives.

Semaglutide shows promise in improving liver health and metabolic outcomes in MASH, enhancing steatohepatitis resolution and cardiometabolic measures.

Few adults with diabetes in Mexico achieve combined CVD risk factor control, highlighting gaps in blood pressure, cholesterol, and glycemic management.

Sleep-focused TNX-102 SL delivered significant benefits in a phase 3 fibromyalgia study.

Explore the evolving GLP-1 landscape with insights from industry experts, shaping future health strategies and plan designs for employers.

As the FY26 budget is being negotiated, Jennifer Snow, MPA, of NAMI, emphasizes that funds must be directed to programs as Congress intends.